Scientific publications

Oliva EN, Cuzzola M, Nobile F, et al. Changes in RPS14 expression levels imiuring lenalidomide treatment in Low-and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion, Eur J. Haematol, 2010; 85:231-5.

Oliva EN, Nobile F, Alimena G, et al. Darbepoetin For The Treatment Of Anemia Of Myelodysplastic Syndromes: Efficacy And Quality Of Life. Leukemia and Lymphoma, 2010; 51(6):1007-14. 

Breccia M, Cannella L, Latagliata R, et al. Unexpected erythroid and cytogenetic responses after discontinuation of short course of lenalidomide due to severe skin rash in a 5q syndrome patient. J Clin Oncol, 2011; May 10;29(14): e 402-3.

Breccia M, Cannella L, Latagliata R, et al. Sudden acute leukemia transformation in a MDS patient with del (5q) in complete cytogenetic remission after lenalidomide. Leuk Res., 2011; 35, 690.

Cannella L, Latagliata R, Breccia M, et al. Very short-term lenalidomide treatment associated with durable resolution of anemia in a patient with myelodysplastic syndrome with chromosome 5q deletion. Ann Hematol, 2012;  Feb; 91 (2):309-10.

Oliva EN, Cuzzola M, Poloni A, et al. Biological activity of lenalidomide in myelodysplastic sindromes with del5q: results of gene expression profiling from a multicenter phase II study. Ann Hematol., 2013;  Jan;92(1):25-32.

Oliva EN, Latagliata R, Laganà C, et al. Lenalidomide in Low-and intermediate-1 IPSS risk myelodysplastic sindromes with del(5q): an Italian phase II trial of health-related quality of life, safety, and efficacy. Leuk Linphoma., 2013;  Nov;54(11):2458-65.

Oliva EN, Lauseker M, Aloe Spiriti MA, at al. Early lenalidomide treatment for low and intermediate-1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence. Cancer Med.2015; Dec; 4(12):1789-97.

Oliva EN, Alati C, Santini V, et al.  Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial. Lancet Haematol. 2017;  Mar;4(3):e127-e136. doi: 10.1016/S2352-3026(17)30012-1.

Congress presentations

Oliva EN, Nobile F., Alimena G., et al. Quality of life in elderly patients with acute myeloid leukemia: patients may be more accurate than physicians. Haematologica. 2011;  May; 96(5):696-702

Oliva EN,  Alati C,  Salutari P, at al. Azacitidine As Post-Remission Therapy in Elderly Patients with Acute Myeloid Leukemia Significantly Prolongs Disease-Free Survival: Interim Results from a Prospective, Randomized, Open-Label, Phase III Multicenter Trial. Blood 2014;  124:2299; by The American Society of Hematology.

Oliva EN, Santini V, Alati C, at al. Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Results on Efficacy, Safety and Quality of Life of an International, Multicenter Prospective, Randomized, Trial.  Blood, 2015; 126:91  by The American Society of Hematology

Oliva EN, Salutari P, Candoni A, et al. Quality of life in elderly patients with acute myeloid leukemia undergoing induction chemotherapy. Blood 2015; 126:2120. by The American Society of Hematology

Cuzzola M, Alati C, Di Bartolomeo P, et al. Biological Markers of relapse in elderly patients with AML in CR after induction consolidation chemotherapy and maintenance with 5-azocitidine. 2016; EHA Learning Center.

Oliva EN, Zappavigna S, Santacaterina I, et al. Surrogate Thresholds for Iron Chelation in Patients with Hematological Malignancies . Oral and Poster Abstracts, Session: 102. Regulation of Iron Metabolism: Poster III, by the American Society of Hematology 2017